A replication-selective adenoviral vector for head and neck cancers.

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge.
• Targeted cancer therapies, including oncolytic virotherapy, offer potential for improved treatment outcomes.
• Cyclo-oxygenase 2 (COX-2) is frequently overexpressed in HNSCC and represents a potential therapeutic target.

Purpose of the Study:

• To evaluate the oncolytic potential of a novel replication-selective adenovirus vector.
• To investigate the efficacy of a COX-2 promoter-driven adenovirus for HNSCC treatment.
• To assess the correlation between COX-2 and Coxsackie and adenovirus receptor (CAR) expression and viral oncolysis in HNSCC cell lines.

Main Methods:

• Generation of a conditional replication-selective adenovirus vector (Ad-COX2-E1a) where viral replication is controlled by the COX-2 promoter.
• In vitro assessment of viral oncolytic activity in a panel of human HNSCC cell lines.
• Quantification of COX-2 and CAR mRNA expression levels in the tested cell lines.

Main Results:

• Variable COX-2 mRNA expression levels were observed across different HNSCC cell lines.
• CAR mRNA expression levels varied among the cell lines.
• Significant in vitro growth suppression was achieved in HNSCC cell lines exhibiting high COX-2 expression.

Conclusions:

• The study demonstrates the feasibility of using a COX-2 promoter-based conditional replication-selective adenovirus for oncolytic therapy.
• This approach shows promise for targeting HNSCC, particularly in tumors with elevated COX-2 expression.
• Further research into COX-2-targeted oncolytic virotherapy for HNSCC is warranted.